HN010 Testing the use of ado-trastuzumab emtansine compared to the usual treatment (chemotherapy with docetaxel plus trastuzumab) for recurrent, metastatic, or unresectable HER2-positive salivary gland cancer

  • Trial Category: Head and Neck

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Methodist Estabrook Cancer Center

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*